TENX

1.25010.07%
SJ

Sanjiv J. Shah

Chairman of Scientific Advisory Board

Dr. Sanjiv J. Shah, FACC, M.D., is Advisor of Axon Therapies Inc. He was Member of Scientific Advisory Board at BaroPace, Inc. since 2024 until February 2026. He serves as Member of Adult Heart Failure Clinical Advisory Board at Secretome Therapeutics, Inc. since 2025 and had been its Member of Clinical Advisory Board from July 2023 to 2025. He has been a Member of PH-Left Heart Disease Scientific Advisory Board at Tenax Therapeutics, Inc. since February 6, 2018 and serves as its Chairman of Scientific Advisory Board from 2025. Dr. Shah is Professor of Medicine and Director of the T1 Center for Cardiovascular Therapeutics at Northwestern University Feinberg School of Medicine. Dr. Shah’s research interests include understanding the physiology, mechanisms and epidemiology of HFpEF. Dr. Shah started the first dedicated HFpEF clinical program at Northwestern University in 2007 and has been a leading enroller in clinical trials for HFpEF since that time. Dr. Shah’s research interests also include the study of acquired and genetic risk factors for abnormal cardiac mechanics and novel machine learning techniques for improved classification and therapeutic targeting of heart failure syndromes. Dr. Shah’s research is currently funded by multiple NIH and American Heart Association grants and he is also a steering committee member for several ongoing international heart failure clinical trials. Dr. Shah has published over 250 original papers, abstracts, book chapters and review articles and he is an Associate Editor for JAMA Cardiology. He has also received several teaching awards throughout his career, including the W. Proctor Harvey Teaching Award from the American College of Cardiology.

Positions